News Blog
We will be adding news on an ongoing basis about our company and products, as well as relevant industry and scientific news.
Posted 2020-03-03
A recent study suggests that AAV gene therapies may not be as safe as once thought. The study found that a gene delivered by AAV has ended up getting integrated into the host genome (this was previously thought not to occur). This could pose potential cancer risk if the gene is inserted in a critical site. This warrants further investigation to determine the long term safety of AAV gene therapies.
Posted 2020-02-03
Johnson & Johnson: “What If You Could Live a Long Life—Disease-Free?”
It’s good to see that Johnson & Johnson (and the National Academy of Medicine) has finally gotten on board with the idea that humans could live very long lives in good health. This is an idea for which we (and many other advocates of longevity and life extension) have advocated for many years. See more here:
“The Quest for ‘Immorbidity’ “
Posted 2019-10-03
Gene therapies will be unaffordable to most unless there is a technical/economic breakthrough.
Read here for the rest of the story.
Posted 2019-08-06
Information regarding Right To Try (RTT) access to experimental new therapies.
Posted 2019-07-02
Below are several useful studies on the cost of new drug development.
Data points regarding the cost of new drug development.
Posted 2019-06-11
Below are three articles describing details related to the high cost of gene therapies and how their price may affect their adoption and medical economics in general.
The price of gene therapies is a major obstacle to their adoption.
Posted 2019-05-20
More excellent and thoughtful analysis by Dr. Mike Fossel on the science of aging and telomeres.
Posted 2019-05-18
A collection of articles providing additional analysis and commentary about the cost of new drug development.
Policy & Medicine, Johns Hopkins School of Public Health, and Forbes, all agree that the cost of new drug development is unnecessarily high.
Posted 2019-05-10
Investment analysts predict life extension medical science to be $600 billion industry by 2025.
We focus more on the science of life extension than the business of life extension. However the business of life extension helps to enable the science, and therefore we must also have appropriate focus on the financial and industry realities as well.
Fortunately, the business of science based life extension therapies is likely to be booming in the coming decades. Bank of America Merrill Lynch analysts predict this industry grow to $600 billion by 2025. They also predict that life extension therapies will likely prolong healthy human life well beyond 100 years, a prediction that we wholeheartedly agree with.
Posted 2019-04-22
Here is an interview with Doug Casey regarding some of the philosophical aspects of life extension science. Our standard disclaimer applies: we do not agree with everything that Mr. Casey has to say, but we agree with much of it, and find the overall interview to be interesting and thought provoking. Some quote-worthy passages below, with our emphasis added:
“These [life extension] technologies will have a wonderful effect on society. As people live longer, their time preferences change. They become less live-in-the-moment and more let’s-look-forward-to-the-future.”
“Life extension could, for instance, have an immense impact on morality. By having a longer timeframe preference, people will likely become much more ethical. They’ll know that they have to live with the consequences of their actions – good and bad – for a long time.”
Posted 2018-11-09
A series of insightful commentaries published at fightaging.org regarding the excessively expensive and heavy-handed nature of regulation of new medical therapies in advanced countries.
Posted 2018-11-02
Here is an outstanding interview with Dr. Mike Fossel of Telocyte. A long interview but well worth reading. There are too many quote-worthy passages to post them all, so we only quote our favorites:
“What I’d like to find is not what causes aging but what the single most effective point of intervention is, clinically and financially. From my perspective, that answer is telomeres and resetting both telomere length and gene expression.”
“We’re now finally, for the first time ever in history, going to be able to prevent and cure age-related diseases. Nothing we have done, ever, up until this point, has had any impact on the fundamental pathology of age-related diseases at all. We’ve all been treating symptoms. That’s about to change.”
